# Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)

> **NCT04722107** · EARLY_PHASE1 · UNKNOWN · sponsor: **Beijing Tongren Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Bietti's Crystalline Dystrophy

## Interventions

- **DRUG:** rAAV2/8-hCYP4V2

## Key facts

- **NCT ID:** NCT04722107
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-21
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-04-29
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722107, "Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04722107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*